SGHT (Sight Sciences) Market Cap: $296.26 Mil (As of Jun. 26, 2026)


SGHT Sight Sciences Inc SGHT
72 GF Score
Price $5.45
GF Value $4.49
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences Market Cap?

Sight Sciences SGHT -0.76% 72 Market Cap is $296.26 Mil as of Jun. 26, 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Sight Sciences ranks better than 62.12% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sight Sciences's share price for the quarter that ended in Mar. 2026 was $3.77. Sight Sciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 54.03 Mil. Therefore, Sight Sciences's market cap for the quarter that ended in Mar. 2026 was $203.71 Mil.

Sight Sciences's quarterly market cap increased from Sep. 2025 ($180.51 Mil) to Dec. 2025 ($424.21 Mil) but then declined from Dec. 2025 ($424.21 Mil) to Mar. 2026 ($203.71 Mil).

Sight Sciences's annual market cap declined from Dec. 2023 ($253.52 Mil) to Dec. 2024 ($185.41 Mil) but then increased from Dec. 2024 ($185.41 Mil) to Dec. 2025 ($424.21 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sight Sciences's Enterprise Value for Today is $253.88 Mil.


Sight Sciences  (NAS:SGHT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Sight Sciences Market Cap Related Terms


Sight Sciences Market Cap Historical Data

* Premium members only.

The historical data trend for Sight Sciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sight Sciences Market Cap Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial 834.66 589.72 253.52 185.41 424.21

Sight Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 123.30 214.90 180.51 424.21 203.71

SGHT vs QSI, TMCI, SI: Market Cap Comparison

For the Medical Devices subindustry, Sight Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sight Sciences Market Cap vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Sight Sciences's Market Cap falls into.


SGHT
72GF Score
Sight Sciences Inc SGHT
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sight Sciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Sight Sciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=$7.93*53.494
=$424.21

Sight Sciences's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=$3.77*54.034
=$203.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $296.26 Mil mean?
Sight Sciences (SGHT) has a Market Cap of $296.26 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sight Sciences and its competitors. According to the industry distribution chart, Sight Sciences ranks #328 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 37.9%.
Is Sight Sciences' Market Cap too high?
Sight Sciences' current Market Cap is $296.26 Mil. The Medical Devices & Instruments industry median Market Cap is 121.29. Sight Sciences' value of $296.26 Mil is 144.3% above this industry median. Based on the distribution chart, Sight Sciences ranks #328 out of 866 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Market Cap compare to QSI and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #328 out of 866 companies for Market Cap. This puts Sight Sciences in the upper half of its industry. The industry median Market Cap is 121.29. Sight Sciences' value of $296.26 Mil is 144.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.29, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Market Cap of $296.26 Mil is 144.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Market Cap is $296.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.45 — trading 21.3% above its estimated fair value. The current Market Cap is $296.26 Mil and 144.3% above the Medical Devices & Instruments industry median of 121.29. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Market Cap is $296.26 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.45 is trading 21.3% above its estimated GF Value™ of $4.49. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • Market Cap: $296.26 Mil
  • GF Value™: $4.49 vs. price of $5.45 (21.3% above fair value)
  • GF Score™: 72/100 with 3 warning signs
  • Industry Position: 144.3% above the Medical Devices & Instruments median (#328 of 866)

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score

Get the complete analysis for SGHT

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.45
Price
$4.49
GF Value